Stroke and the antiphospholipid syndrome: Consensus meeting Taormina 2002

R. L. Brey, J. Chapman, S. R. Levine, G. Ruiz-Irastorza, R. H.W.M. Derksens, M. Khamashta, Y. Shoenfeld

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Ischaemic stroke is the only neurological manifestation accepted as a clinical diagnostic criterion for the antiphospholipid syndrome (APS). This association is reasonably well established in patients first diagnosed with APS but is less clear in randomly selected stroke patients who test positive on one occasion for antiphospholipid antibodies and who have no other evidence of systemic autoimmmune disease. We propose a grading system that posits stroke to be definitely, likely or possibly associated with antiphospholipid antibodies (aPL). Further, there are limited prospective data to determine appropriate treatment. There is controversy as to whether the presence of aPL even increases risk of a recurrent stroke or other thromboembolic event, although data point to persistent medium-high titre aCL and/or LA as risk factors for recurrence. In the absence of data to guide clinicians on the best treatment, we cannot make strong recommendations as to optimal therapy, nor can we propose clear consensus treatment guidelines.

Original languageEnglish (US)
Pages (from-to)508-513
Number of pages6
Issue number7
StatePublished - 2003


  • Anticoagulant therapy
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Cerebrovascular disorders
  • Lupus anticoagulant
  • Stroke

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Stroke and the antiphospholipid syndrome: Consensus meeting Taormina 2002'. Together they form a unique fingerprint.

Cite this